Furthermore, vaccination that primed the tumour-specific CD4+ T cells enhanced the responses of tumour (Env/Kb and GagL/Db)21-specific CD8+ T cells in aged mice only when anti-IL-6 Ab was administered at the CD4+ T-cell-priming phase (Fig. 7f). The gene discussed is ERVW-1; the disease is neoplasm.